EX-4.4 5 d800188dex44.htm EX-4.4 EX-4.4

Exhibit 4.4

 

LOGO

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JULY 31, 2020 AND 2019

(Unaudited – Expressed in Canadian Dollars)


IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited – Expressed in Canadian Dollars)

 

 

            July 31,     April 30,  
            2020     2020  
     Note      $     $  

ASSETS

       

Current assets

       

Cash

        6,062,177       2,605,706  

Amounts receivable

        3,599,869       2,491,636  

Taxes receivable

        —         88,549  

Inventory

        1,017,677       818,643  

Unbilled revenue

        1,868,097       1,168,317  

Prepaid expenses

        447,106       526,591  
     

 

 

   

 

 

 
        12,994,926       7,699,442  

Restricted cash

        84,457       85,129  

Deposit on equipment

        —         87,847  

Investment

     7        127,394       118,896  

Property and equipment

     8        3,651,390       3,077,762  

Intangible assets

     5, 6, 9        8,229,778       8,285,392  

Goodwill

     5, 6        8,332,782       7,908,653  
     

 

 

   

 

 

 

Total assets

        33,420,727       27,263,121  
     

 

 

   

 

 

 

LIABILITIES

       

Current liabilities

       

Accounts payable and accrued liabilities

        2,316,814       1,766,058  

Taxes payable

        171,429       —    

Deferred revenue

        2,328,007       1,474,750  

Debentures

     10        —         2,000,000  

Loans payable

     11        107,287       121,833  

Leases

     13        698,715       752,306  

Deferred acquisition payments

     5, 6        1,976,379       1,814,820  
     

 

 

   

 

 

 
        7,598,631       7,929,767  

Debenture subscriptions received

     12        —         313,268  

Loans payable

     11        189,099       190,306  

Convertible debentures – liability component

     12        2,341,765       —    

Leases

     13        1,687,957       1,131,744  

Deferred acquisition payments

     5, 6        —         1,010,620  

Deferred income tax liability

        1,687,468       1,601,577  
     

 

 

   

 

 

 
        13,504,920       12,177,282  
     

 

 

   

 

 

 

SHAREHOLDERS’ EQUITY

       

Share capital

     14        38,401,865       34,086,942  

Convertible debentures – equity component

     12        204,523       —    

Contributed surplus

     14        3,722,646       3,777,771  

Accumulated other comprehensive income (loss)

        614,743       (300,222

Deficit

        (23,027,970     (22,478,652
     

 

 

   

 

 

 
        19,915,807       15,085,839  
     

 

 

   

 

 

 

Total liabilities and shareholders’ equity

        33,420,727       27,263,121  
     

 

 

   

 

 

 

Nature of operations (Note 1)

Subsequent events (Notes 14 and 18)

Approved and authorized on behalf of the Board of Directors on September 28, 2020

 

        “James Kuo”         

   Director   

        “Greg Smith”         

   Director                

The accompanying notes are an integral part of these condensed interim consolidated financial statements

 

2


IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF

COMPREHENSIVE INCOME (LOSS)

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

            2020     2019  
     Note      $     $  

REVENUE

        3,764,977       2,716,099  

COST OF SALES

        1,354,651       1,339,693  
     

 

 

   

 

 

 

GROSS PROFIT

        2,410,326       1,376,406  
     

 

 

   

 

 

 

EXPENSES

       

Advertising

        33,306       117,200  

Amortization and depreciation

     8, 9        677,887       547,841  

Bad debt recovery

        (15,775     —    

Consulting fees

        37,421       22,340  

Foreign exchange loss (gain)

        20,256       (112,976

Insurance

        35,692       20,531  

Interest and bank charges

        169,806       118,960  

Management fees

     15        196,539       45,148  

Office and general

        148,160       223,335  

Professional fees

        187,674       149,720  

Rent

        96,656       41,165  

Repairs and maintenance

        8,439       —    

Research and development

        309,213       167,260  

Salaries and benefits

     15        1,351,232       1,096,244  

Share-based payments

     14, 15        97,273       285,995  

Telephone and utilities

        12,973       10,100  

Travel

        17,400       119,305  
     

 

 

   

 

 

 
        3,384,152       2,852,168  
     

 

 

   

 

 

 

Loss before other income (expense) and income taxes

        (973,826     (1,475,762
     

 

 

   

 

 

 

OTHER INCOME (EXPENSE)

       

Accretion

     5, 6, 10, 12        (101,145     (552,893

Grant income and subsidy

        707,284       —    

Other expense

        (624     12,402  
     

 

 

   

 

 

 
        605,515       (540,491
     

 

 

   

 

 

 

Loss before income taxes

        (368,311     (2,016,253

Income taxes (expense) recovery

        (181,007     4,055  
     

 

 

   

 

 

 

NET LOSS FOR THE PERIOD

        (549,318     (2,012,198

ITEMS THAT MAY BE RECLASSIFIED SUBSEQUENTLY TO LOSS

       

Exchange difference on translating foreign operations

        914,965       (602,604
     

 

 

   

 

 

 

COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD

        365,647       (2,614,802
     

 

 

   

 

 

 

LOSS PER SHARE – BASIC AND DILUTED

        (0.01     (0.03
     

 

 

   

 

 

 

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING

        72,414,998       67,982,923  
     

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements

 

3


IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited – Expressed in Canadian dollars, except for share figures)

 

 

                      Convertible           Accumulated              
                      Debentures           Other              
          Share     Subscriptions     – Equity     Contributed     Comprehensive              
    Number of     Capital     Received     Component     Surplus     (Loss) Income     Deficit     Total  
    Shares     $     $     $     $     $     $     $  

Balance, April 30, 2019

    67,939,445       32,699,425       —         —         3,074,192       (228,060     (17,476,482     18,069,075  

Adoption of IFRS 16 (Note 4)

    —         —         —         —         —         —         (54,744     (54,744
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance, May 1, 2019

    67,939,445       32,699,425       —         —         3,074,192       (228,060     (17,531,226     18,014,331  

Subscriptions received

    —         —         1,500       —         —         —         —         1,500  

Shares issued pursuant to option exercise

    50,000       26,355       —         —         (11,355     —         —         15,000  

Share-based payments

    —         —         —         —         285,995       —         —         285,995  

Comprehensive loss for the period

    —         —         —         —         —         (602,604     (2,012,198     (2,614,802
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance, July 31, 2019

    67,989,445       32,725,780       1,500       —         3,348,832       (830,664     (19,543,424     15,702,024  

Shares issued pursuant to settlement of Debentures and accrued interest

    1,244,792       858,906       —         —         —         —         —         858,906  

Shares issued pursuant to option exercise

    5,000       2,635       (1,500     —         (1,135     —         —         —    

Shares issued pursuant to warrant exercise

    680,971       499,621       —         —         (22,942     —         —         476,679  

Share-based payments

    —         —         —         —         453,016       —         —         453,016  

Comprehensive loss for the period

    —         —         —         —         —         530,442       (2,935,228     (2,404,786
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance, April 30, 2020

    69,920,208       34,086,942       —         —         3,777,771       (300,222     (22,478,652     15,085,839  

Shares issued pursuant to deferred acquisition payment to IPA Europe

    664,163       511,405       —         —         —         —         —         511,405  

Shares issued pursuant to option exercise

    180,900       237,044       —         —         (99,199     —         —         137,845  

Shares issued pursuant to warrant exercise

    3,305,500       3,566,474       —         —         (53,199     —         —         3,513,275  

Convertible debentures

    —         —         —         204,523       —         —         —         204,523  

Share-based payments

    —         —         —         —         97,273       —         —         97,273  

Comprehensive income (loss) for the period

    —         —         —         —         —         914,965       (549,318     365,647  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance, July 31, 2020

    74,070,771       38,401,865       —         204,523       3,722,646       614,743       (23,027,970     19,915,807  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements

 

4


IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

     2020     2019  
     $     $  

Operating activities:

    

Net loss for the period

     (549,318     (2,012,198

Items not affecting cash:

    

Amortization and depreciation

     911,923       702,284  

Deferred income taxes

     —         (55,140

Accretion

     101,145       552,893  

Foreign exchange

     110,932       (118,983

Share-based payments

     97,273       285,995  
  

 

 

   

 

 

 
     671,955       (645,149

Changes in non-cash working capital related to operations:

    

Amounts receivable

     (1,108,233     217,161  

Inventory

     (199,034     101,746  

Unbilled revenue

     (699,780     155,970  

Prepaid expenses

     79,485       15,172  

Accounts payable and accrued liabilities

     550,756       (319,074

Taxes payable and receivable

     259,978       141,532  

Deferred revenue

     853,257       89,128  
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     408,384       (243,514
  

 

 

   

 

 

 

Investing activities:

    

Purchase of equipment

     (10,566     (70,894

Internally generated development costs

     (21,049     (10,621

Deferred acquisition payment

     (518,534     —    
  

 

 

   

 

 

 

Net cash used in investing activities

     (550,149     (81,515
  

 

 

   

 

 

 

Financing activities:

    

Proceeds on share issuance

     3,651,120       15,000  

Subscriptions received

     —         1,500  

Repayment of leases

     (267,103     (105,075

Loan repayments

     (15,753     (20,398

Proceeds from convertible debentures, net of transaction costs

     2,201,821       —    

Repayment of debentures

     (2,000,000     —    
  

 

 

   

 

 

 

Net cash provided by financing activities

     3,570,085       (108,973
  

 

 

   

 

 

 

Increase (decrease) in cash during the period

     3,428,320       (434,002

Foreign exchange

     27,479       (116,311

Cash – beginning of the period

     2,690,835       5,539,100  
  

 

 

   

 

 

 

Cash – end of the period

     6,146,634       4,988,787  
  

 

 

   

 

 

 

Cash is comprised of:

    

Cash

     6,062,177       4,951,871  

Restricted cash

     84,457       36,916  
  

 

 

   

 

 

 
     6,146,634       4,988,787  
  

 

 

   

 

 

 

Cash paid for interest

     61,644       1,196  

Cash paid for income tax

     10,088       30,315  

Supplemental cash flow information (Note 17)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

 

5


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

1.

NATURE OF OPERATIONS

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) was incorporated under the laws of Alberta on November 22, 1983. The Company is listed on the TSX Venture Exchange (the “Exchange”) as a Tier 2 life science issuer under the trading symbol “IPA”. The Company’s OTC symbol is “IPATF”. The Company is a supplier of custom hybridoma development services. The address of the Company’s corporate office is 3204 – 4464 Markham Street, Victoria, BC, Canada V8Z 7X8.

The condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. This assumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its obligations in the normal course of operations. The Company has incurred operating losses since inception, including $549,318 for the three months ended July 31, 2020 and has accumulated a deficit of $23,027,970 as at July 31, 2020. The Company may need to raise additional funds in order to continue on as a going concern and there can be no assurances that sufficient funding, including adequate financing, will be available. The ability of the Company to arrange additional financing in the future depends in part, on the prevailing capital market conditions and profitability of its operations.

In March 2020, there was a global pandemic outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and specifically, the regional economies in which the Company operates. The pandemic could result in delays in the course of business and could have a negative impact on the Company’s ability to raise new capital. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations at this time. These material uncertainties may cast significant doubt on the Company’s ability to continue as a going concern. Accordingly, the condensed interim consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities, contingent obligations and commitments other than in the normal course of business and at amounts different from those in the condensed interim consolidated financial statements.

 

2.

BASIS OF PRESENTATION

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in conformity with International Accounting Standard (“IAS”) 34, Interim Financial Reporting, using the same accounting policies as detailed in the Company’s audited annual financial statements for the year ended April 30, 2020. They do not include all the information required for complete annual financial statements in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) and therefore should be read together with the audited annual financial statements for the year ended April 30, 2020.

These condensed interim consolidated financial statements were approved by the Board of Directors for issue on September 28, 2020.

(b) Basis of measurement

These condensed interim consolidated financial statements have been prepared on the historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information.

 

6


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

(c) Basis of consolidation

These condensed interim consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company:

 

Name of Subsidiary

   % Equity
Interest - 2020
    % Equity
Interest - 2019
    Country of
Incorporation

ImmunoPrecise Antibodies (Canada) Ltd.

     100     100   Canada

ImmunoPrecise Antibodies (USA) Ltd.

     100     100   USA

ImmunoPrecise Antibodies (N.D.) Ltd.

     100     100   USA

ImmunoPrecise Antibodies (MA) LLC

     100     100   USA

Talem Therapeutics LLC

     100     100   USA

U-Protein Express B.V. (“U-Protein”)

     100     100   Netherlands

ImmunoPrecise Netherlands B.V.

     100     100   Netherlands

ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”, formerly ModiQuest Research B.V.)

     100     100   Netherlands

Immulease B.V. (“Immulease”)

     100     100   Netherlands

Control is achieved when the Company has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation.

The Company incorporated a new subsidiary, ImmunoPrecise Antibodies (USA) Ltd., in Delaware, USA on September 11, 2019.

(d) Functional and presentation currency

The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.

The functional currency of the Company and ImmunoPrecise Antibodies (Canada) Ltd. is the Canadian dollar. The functional currency of ImmunoPrecise Antibodies (USA) Ltd., ImmunoPrecise Antibodies (N.D.) Ltd., ImmunoPrecise Antibodies (MA) LLC and Talem Therapeutics LLC is the US dollar. The functional currency of U-Protein, ImmunoPrecise Netherlands BV, IPA Europe and Immulease is the Euro. The presentation currency of the Company is the Canadian dollar.

Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences.

Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss.

 

7


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

 

3.

ADOPTION OF NEW ACCOUNTING STANDARDS

The Company has adopted the following new standards, along with any consequential amendments, effective May 1, 2019. These changes were made in accordance with the applicable transitional provisions.

The Company adopted all of the requirements of IFRS 16, Leases (“IFRS 16”) as of May 1, 2019. IFRS 16 replaces IAS 17, Leases (“IAS 17”). IFRS 16 provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. The Company has adopted IFRS 16 using the modified retrospective application method, where the 2019 comparatives are not restated and a cumulative catch up adjustment is recorded on May 1, 2019 for any differences identified, including adjustments to opening deficit balance.

The Company analyzed its contracts to identify whether they contain a lease arrangement for the application of IFRS 16. The following is the Company’s new accounting policy for leases under IFRS 16:

At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, and otherwise at the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received.

Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life and the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life.

On the date of transition, the Company recorded a right-of-use asset of $1,668,533 related to the office rent in property and equipment, and the lease obligation of $1,723,277 was recorded as at May 1, 2019, discounted using the Company’s incremental borrowing rate of 8%, and measured at an amount equal to the lease obligation as if IFRS 16 had been applied since the commencement date. The net difference between right-of-use assets and lease liabilities on the date of transition was recognized as a deficit adjustment of $54,744 on May 1, 2019.

 

8


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

4.

CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of the condensed interim consolidated financial statements in conformity with IFRS required estimates and judgments that affect the amounts reported in the financial statements. Actual results could differ from these estimates and judgments. Estimates are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised. Significant areas requiring the use of estimates and judgments are as follows:

Functional currency

The Company has used judgment in determining the currency of the primary economic environment in which the entity operates.

Amounts receivable

The Company monitors the financial stability of its customers and the environment in which they operate to make estimates regarding the likelihood that the individual trade receivable balances will be paid. Credit risks for outstanding customer receivables are regularly assessed and allowances are recorded for estimated losses, if required.

Property and equipment

The Company has used estimates in the determination of the expected useful lives of property and equipment.

Revenue recognition

The percentage-of-completion method requires the use of estimates to determine the stage of completion which is used to determine the recorded amount of revenue, unbilled revenue and deferred revenue on uncompleted contracts. The determination of anticipated revenues includes the contractually agreed revenue and may also involve estimates of future revenues if such additional revenues can be reliably estimated and it is considered probable that they will be recovered. The determination of anticipated costs for completing a contract is based on estimates that can be affected by a variety of factors, including the cost of materials, labour, and sub-contractors. The determination of estimates is based on the Company’s business practices as well as its historical experience.

Impairments

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”s). Each asset or CGU is evaluated every reporting period to determine whether there are any indicators of impairment. If any such indicators exist, which is often judgment-based, a formal estimate of recoverable amount is performed and an impairment charge is recognized to the extent that the carrying amount exceeds the recoverable amount. The recoverable amount of an asset or CGU of assets is measured at the higher of fair value less costs of disposal or value in use. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period. The estimates and assumptions are subject to risk and uncertainty; hence, there is the possibility that changes in circumstances will alter these projections, which may impact the recoverable amount of the assets. In such circumstances, some or all of the carrying value of the assets may be further impaired or the impairment charge reversed with the impact recorded in profit or loss.

The Company performs a goodwill impairment test annually and when circumstances indicate that the carrying value may not be recoverable. For the purposes of impairment testing, goodwill acquired through business combinations has been allocated to two different CGUs. The recoverable amount of each CGU was based on value in use, determined by discounting the future cash flows to be generated from the continuing use of the CGU. The cash flows were projected over a five-year period based on past experience and actual operating results.

 

9


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The Company performed its annual goodwill impairment test in April 2020 and no impairment was indicated for the period tested. The values assigned to the key assumptions represented management’s assessment of future trends in the industry and were based on hgarristorical data from both internal and external sources. Weighted average costs of capital of 16.33% and 12.26%, respectively, was used in the assessments of the two CGUs.

Determination of segments

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. All operating segments’ results are reviewed by the Company’s management in order to make decisions regarding the allocation of resources to the segment. Segment results include items directly attributable to a segment as those that can be allocated on a reasonable basis.

As the Company provides antibody production and related services in one distinct segment.

Life of intangible assets

Intangible assets are amortized based on estimated useful life less their estimated residual value. Significant assumptions are involved in the determination of useful life and residual values and no assurance can be given that actual useful lives and residual values will not differ significantly from current assumptions. Actual useful life and residual values may vary depending on a number of factors including internal technical evaluation, attributes of the assets and experience with similar assets. Changes to these estimates may affect the carrying value of assets, net income (loss) and comprehensive income (loss) in future periods.

Purchase price allocation

The acquisition of U-Protein on August 22, 2017 and the acquisition of IPA Europe and Immulease on April 5, 2018 were accounted for as business combinations at fair value in accordance with IFRS 3, Business Combinations. The acquired assets and assumed liabilities were adjusted to their fair values assigned through completion of a purchase price allocation, as described below.

The purchase price allocation process resulting from a business combination required management to estimate the fair value of identifiable assets acquired including intangible assets and liabilities assumed including the deferred acquisition payment obligations. The Company used valuation techniques, which were based on forecasted future net cash flows discounted to present value, and also relied on work performed by third-party valuation specialists. These valuations were closely linked to the assumptions used by management on the future performance of the related assets and the discount rates applied.

 

5.

ACQUISITION OF U-PROTEIN

On August 22, 2017, the Company completed the acquisition of U-Protein whereby the Company acquired all of the issued and outstanding shares of U-Protein for €6,830,000 on terms as follows:

 

   

€2,734,732 (CAD$4,062,607) was paid in cash on closing;

 

   

3,030,503 common shares of the Company were issued on closing; and

 

   

€2,047,634 in deferred payments over a three-year period. The deferred payments can be made in cash or common shares of the Company at the election of U-Protein shareholders.

The transaction was accounted for as a business combination, as the operations of U-Protein meet the definition of a business. As the transaction was accounted for as a business combination, transaction costs of $17,717 were expensed. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets represented the sales and growth potential of U-Protein. Goodwill recorded is allocated in its entirety to U-Protein. The fair value of the 3,030,503 common shares issued ($3,022,308) was determined based on the Canadian dollar equivalent of the consideration required of €2,047,634 pursuant to the share purchase agreement. The Company has allocated the purchase price as follows:

 

10


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

     $  

Cash

     4,062,607  

3,030,503 common shares of the Company

     3,022,308  

Fair value of deferred payments

     2,134,410  
  

 

 

 

Fair value of consideration

     9,219,325  
  

 

 

 

Cash

     797,276  

Amounts receivable

     370,530  

Unbilled revenue

     112,815  

Inventory

     36,900  

Investment

     90,404  

Equipment, net of accumulated amortization

     216,161  

Intellectual property (not deductible for tax purposes)

     4,064,000  

Goodwill (not deductible for tax purposes)

     4,655,893  

Accounts payable and accrued liabilities

     (269,657

Income taxes payable

     (44,197

Deferred income tax liability

     (810,800
  

 

 

 
     9,219,325  
  

 

 

 

The deferred payments of €2,047,634 over a three-year period was fair valued on the date of acquisition using a discounted cash flow model. A discount rate of 16.2% was used. The changes in the value of the deferred payments during the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     $  

Balance, April 30, 2019

     1,562,696  

Accretion expense

     350,137  

Payment

     (1,007,435

Foreign exchange

     26,130  
  

 

 

 

Balance, April 30, 2020

     931,528  

Accretion expense

     36,983  

Foreign exchange

     47,541  
  

 

 

 

Balance, July 31, 2020

     1,016,052  
  

 

 

 

 

6.

ACQUISITION OF IPA EUROPE AND IMMULEASE

On April 5, 2018, the Company acquired all of the issued and outstanding shares of IPA Europe and its sister entity, Immulease, for an aggregate purchase price of €7,000,000 on terms as follows:

 

   

€2,500,000 (CAD$3,988,132) was paid in cash on closing;

 

   

6,600,399 common shares of the Company were issued on closing; and

 

   

€2,000,000 in deferred payments over a three-year period. The deferred payments are made in three equal installments of cash and equity totaling €666,666 and prorated if the EBITDA of IPA Europe for the fiscal year preceding the date of payment is less than its average EBITDA over the previous two fiscal years. During the year ended April 30, 2019, the Company and the seller entered into an Amendment, Termination and Settlement Agreement whereby the deferred payments shall no longer be subject to an adjustment and will be paid in equal installments of cash and equity totaling €666,666.

The transaction was accounted for as a business combination, as the operations of IPA Europe and Immulease meet the definition of a business. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets represented the sales and growth potential of IPA Europe. Goodwill recorded is

 

11


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

allocated in its entirety to IPA Europe. The fair value of the 6,600,399 common shares issued ($4,884,295) was determined to be $0.74 per share based on the fair value of the Company’s shares immediately prior to the completion of the acquisition. The Company has allocated the purchase price as follows:

 

     $  

Cash

     3,988,132  

6,600,399 common shares of the Company

     4,884,295  

Fair value of deferred payments

     2,353,708  
  

 

 

 

Fair value of consideration

     11,226,135  
  

 

 

 

Cash

     270,339  

Amounts receivable

     572,427  

Unbilled revenue

     90,052  

Inventory

     2,286,995  

Equipment, net of accumulated amortization

     568,221  

Software

     30,974  

Intangible assets (not deductible for tax purposes)

     6,304,863  

Goodwill (not deductible for tax purposes)

     3,640,671  

Accounts payable and accrued liabilities

     (580,339

Deferred revenue

     (22,897

Loans

     (298,979

Deferred income tax liability

     (1,636,192
  

 

 

 
     11,226,135  
  

 

 

 

The deferred payments of €2,000,000 over a three-year period was fair valued on the date of acquisition using a discounted cash flow model. A discount rate of 14% was used. The changes in the value of the deferred payments during the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     $  

Balance, April 30, 2019

     1,501,285  

Accretion expense

     382,928  

Foreign exchange

     9,699  
  

 

 

 

Balance, April 30, 2020

     1,893,912  

Accretion expense

     32,963  

Repayment

     (1,029,939

Foreign exchange

     63,391  
  

 

 

 

Balance, July 31, 2020

     960,327  
  

 

 

 

 

7.

INVESTMENT

Investment consists of a 29% (2019 – 29%) interest in QVQ Holding B.V. (“QVQ”), which is recorded using the equity method, being the best approximation of the investment’s fair value. Judgment is required as to the extent of influence that the Company has over QVQ. The Company considered the extent of voting power over the entity, the power to participate in financial and operating policy decisions of the entity, representation on the board of directors, material transactions between the entities, interchange of management personnel, and provision of essential technical information. The Company has determined that the Company is not considered to have significant influence over QVQ, as the Company does not have the power to participate in financial and operating policy decisions, does not have representation on the Board of Directors of QVQ, and the majority of the common shares are held by QVQ management.

 

12


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

8.

PROPERTY AND EQUIPMENT

 

     Computer
Hardware
    Furniture &
Equipment
    Computer
Software
    Building     Automobile      Leasehold
Improvements
    Lab
Equipment
    Total  
     $     $     $     $     $      $     $     $  

Cost:

                 

Balance, April 30, 2019

     110,997       111,065       130,015       —         —          393,421       3,369,010       4,114,508  

IFRS 16 transition adjustment

     —         —         —         1,668,533       —          —         —         1,668,533  

Additions

     16,999       —         —         905,225       48,997        6,495       350,260       1,327,976  

Disposals

     (73,697     (75,052     (80,193     (196,325     —          (49,221     (633,152     (1,107,640

Foreign exchange

     —         —         97       6,166       972        —         12,367       19,602  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Balance, April 30, 2020

     54,299       36,013       49,919       2,383,599       49,969        350,695       3,098,485       6,022,979  

Additions

     2,236       —         —         —         —          —         865,902       868,138  

Foreign exchange

     (28     —         1,605       78,082       2,680        —         119,011       201,350  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Balance, July 31, 2020

     56,507       36,013       51,524       2,461,681       52,649        350,695       4,083,398       7,092,467  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Accumulated Depreciation:

                 

Balance, April 30, 2019

     88,135       85,636       48,789       —         —          205,816       2,047,583       2,475,959  

Depreciation

     23,016       7,194       66,198       696,948       7,145        69,273       497,409       1,367,183  

Disposals

     (73,697     (75,052     (80,193     —         —          (49,221     (633,152     (911,315

Foreign exchange

     —         —         170       3,366       142        —         9,712       13,390  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Balance, April 30, 2020

     37,454       17,778       34,964       700,314       7,287        225,868       1,921,552       2,945,217  

Depreciation

     8,085       1,781       1,972       175,123       3,291        17,534       184,902       392,688  

Foreign exchange

     —         —         801       20,739       390        —         81,242       103,172  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Balance, July 31, 2020

     45,539       19,559       37,737       896,176       10,968        243,402       2,187,696       3,441,077  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Net Book Value:

                 

April 30, 2020

     16,845       18,235       14,955       1,683,285       42,682        124,827       1,176,933       3,077,762  

July 31, 2020

     10,968       16,454       13,787       1,565,505       41,681        107,293       1,895,702       3,651,390  

 

9.

INTANGIBLE ASSETS

The intangible assets were acquired as a result of the acquisitions of U-Protein and IPA Europe and are amortized using the straight-line method over their useful lives. The intellectual property has a useful life of 10 years, and the proprietary processes have a useful life of 5 years. The internally generated development costs will commence amortizing once the development process is ready to be used. The changes in the value of the intangible assets during the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     Internally
Generated
Development
Costs
     Intellectual
Property
     Proprietary
Processes
     Certifications      Total  
     $      $      $      $      $  

Cost:

              

Balance, April 30, 2019

     —          4,145,225        7,740,010        139,707        12,024,942  

Additions

     114,042        —          —          —          114,042  

Foreign exchange

     533        13,464        25,140        454        39,591  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Balance, April 30, 2020

     114,575        4,158,689        7,765,150        140,161        12,178,575  

Additions

     21,049        —          —          —          21,049  

Foreign exchange

     4,383        223,024        416,433        7,517        651,357  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Balance, July 31, 2020

     140,007        4,381,713        8,181,583        147,678        12,850,981  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Accumulated Amortization:

              

Balance, April 30, 2019

     —          635,601        1,162,592        —          1,798,193  

Amortization

     —          406,334        1,634,830        —          2,041,164  

Foreign exchange

     —          11,600        42,226        —          53,826  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Balance, April 30, 2020

     —          1,053,535        2,839,648        —          3,893,183  

Amortization

     —          109,543        409,692        —          519,235  

Foreign exchange

     —          56,499        152,286        —          208,785  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Balance, July 31, 2020

     —          1,219,577        3,401,626        —          4,621,203  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Book Value:

              

April 30, 2020

     114,575        3,105,154        4,925,502        140,161        8,285,392  

July 31, 2020

     140,007        3,162,136        4,779,957        147,678        8,229,778  

 

13


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

10.

DEBENTURES

On April 5, 2018, the Company completed a nonconvertible debenture (the “Debentures”) financing in the principal amount of $4,252,000 (the “Offering”). The Debentures were unsecured, bore interest at a rate of 10% per annum, payable semi-annually, and were due eighteen months from the date of issue. Under the Offering, a holder of a Debenture received 37,500 detachable share purchase warrants (the “Warrants”) for every $25,000 of Debentures subscribed for by the holder. The Warrants are exercisable at $0.70 per share for a period of four years from the date of issue. The fair value of the Debentures at the time of issue was calculated as the discounted cash flows assuming a 15% effective interest rate. The fair value of the Warrants was determined at the time of issue as the difference between the face value and the fair value of the Debentures. On initial recognition, the Company bifurcated $4,003,125 to the carrying value of the Debentures and $248,875 to the Warrants.

Under the Offering, the Company paid the following finder’s fees: $10,300 in cash, 580,320 shares of the Company with a fair value of $383,010, and 415,942 finder’s warrants valued at $187,627. The fair value of the finder’s warrants was estimated on the date of issue using the Black-Scholes option valuation model with the following weighted average assumptions: dividend yield of $nil, risk free interest rate of 1.60%, expected life of 4 years and expected volatility based on the historical volatility of similar companies of 100%. The total fair value of the finder’s fees was allocated pro-rata based on the carrying values of the Debentures and Warrants, with $546,934 allocated to the Debentures and $34,003 allocated to the Warrants.

On October 25, 2018, the Company settled $1,377,000 of the Debentures by issuing 1,377,000 units at a price of $1.00 per unit. Each unit consisted of one common share of the Company and one share purchase warrant, with each warrant entitling the holder to purchase an additional share at $1.25 for two years. The fair value of the 1,377,000 common shares issued was determined to be $1,115,370. The fair value of the warrants issued was determined to be $283,000 and estimated on the date of issue using the Black-Scholes option valuation model with the following weighted average assumptions: dividend yield of $nil, risk free interest rate of 1.58%, expected life of 2 years and expected volatility based on the historical volatility of similar companies of 68.7%. The settlement resulted in a loss of $189,715.

On September 26, 2019, the Company modified the terms of $2,750,000 Debentures to extend the due date by 6 months to March 26, 2020, with the ability to pay earlier with no penalty, and increased the interest rate to 12.5%. The remaining debentures of $125,000 were paid on maturity.

On March 26, 2020, the Company settled $700,000 of the Debentures plus accrued interest of $46,875 by issuing 1,244,792 common shares. The fair value of the 1,244,792 common shares issued was determined to be $858,906. The settlement resulted in a loss of $112,031. $50,000 of the Debentures were paid on maturity. The maturity date of the remaining Debentures of $2,000,000 was extended to September 26, 2020.

 

14


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The Company repaid the remaining balance of $2,000,000 plus interest during the three months ended July 31, 2020.

The changes in the value of the Debentures during the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     $  

Balance, April 30, 2019

     2,708,334  

Accretion expense

     166,666  

Repayment

     (175,000

Settlement of debentures

     (700,000
  

 

 

 

Balance, April 30, 2020

     2,000,000  

Repayment

     (2,000,000
  

 

 

 

Balance, July 31, 2020

     —    
  

 

 

 

 

11.

LOANS PAYABLE

On April 5, 2018, the Company assumed loans payable of €60,750 (CAD$94,995) as a result of the acquisition of IPA Europe. On July 7, 2015, IPA Europe entered into a loan agreement in the principal amount of €165,000, maturing on July 31, 2020. The loan was secured by certain equipment, bore an interest rate of 4% per annum and was repayable in monthly installments of €2,250. The interest was owed per month in arrears. The principal outstanding at July 31, 2020 is €nil (CAD$nil) (April 30, 2020 – €4,500 (CAD$6,797)).

On April 5, 2018, the Company assumed loans payable of €56,450 (CAD$88,271) as a result of the acquisition of IPA Europe. On February 1, 2016, IPA Europe entered into a loan agreement in the principal amount of €100,000, maturing on February 28, 2021. The loan is secured by certain equipment, bears an interest rate of 3% per annum and is repayable in monthly installments of €1,675. The interest is owed per month in arrears. The principal outstanding at July 31, 2020 is €9,550 (CAD$15,198) (April 30, 2020 – €14,575 (CAD$22,014)).

On April 15, 2020, the Company was approved for a US$209,000 loan under the Payroll Protection Program (“PPP”) administered by the U.S. Small Business Administration. The loan accrues interest at 1% per annum and is repayable in monthly installments of US$11,761 starting in November 2020 until April 2022. The PPP is a US$349 billion loan program that originated from the U.S. Coronavirus Aid, Relief and Economic Security (CARES) Act. The PPP loan has a term of two years, is unsecured, and is guaranteed by the U.S. Small Business Administration. The loan will be forgiven if the proceeds are used by the Company to cover payroll costs (including benefits), with up to 25% allowed for rent and utilities, during the eight-week period following the loan origination date. The Company expects to meet the requirements for full loan forgiveness and will apply for lender forgiveness after the required September 30, 2020 federal and state employment related filings are complete.

 

15


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

     $  

Balance, April 30, 2019

     111,670  

Loan proceeds

     283,328  

Loan repayments and foreign exchange

     (82,859
  

 

 

 

Balance, April 30, 2020

     312,139  

Loan repayments and foreign exchange

     (15,753
  

 

 

 

Balance, July 31, 2020

     296,386  

Current portion

     (107,287
  

 

 

 

Non-current portion

     189,099  
  

 

 

 

 

12.

CONVERTIBLE DEBENTURES

On May 15, 2020, the Company closed a non-brokered private placement financing by issuing 10% convertible debentures (“New Debentures”) for total proceeds of $2,592,000. On May 27, 2020, the Company issued an additional $35,000 of the 10% New Debentures. In total, the Company issued $2,627,000 of the New Debentures. The New Debentures are unsecured, bear interest at a rate of 10% per year and payable at maturity. The maturity date is May 15, 2022 for $2,592,000 of the New Debentures and May 22, 2022 for $35,000 of the New Debentures. The principal amount of the New Debentures may be convertible, at the option of the holder, into units of the Company at a conversion price of $0.85 per share. The Company may force convert the principal amount of the New Debentures at $0.85 per share if the average closing price is equal to or greater than $1.50 for 20 trading days.

In advance of the closing of the New Debentures, the Company had received $313,268 of the proceeds as at April 30, 2020.

The fair value of the New Debentures at the time of issue was calculated as the discounted cash flows assuming a 15% effective interest rate. The fair value of the equity component was determined at the time of issue as the difference between the face value and the fair value of the New Debentures. On initial recognition, the Company bifurcated $2,413,377 to the carrying value of the New Debentures and $213,623 to the equity component.    

Under the financing, the Company paid finders cash commissions totaling $82,580 and incurred legal and filing fees of $29,331. The transaction costs were allocated pro-rata based on the carrying values of the New Debentures and the equity component, with $102,811 allocated to the New Debentures and $9,100 allocated to the equity component.

During the three months ended July 31, 2020, the Company recorded accretion expense of $31,199 (2019 – $nil). The changes in the value of the New Debentures during the three months ended July 31, 2020 are as follows:

 

     Liability
Component
     Equity
Component
 
     $      $  

Balance, April 30, 2020

     —          —    

Proceeds

     2,413,377        213,623  

Transaction costs

     (102,811      (9,100

Accretion expense

     31,199        —    
  

 

 

    

 

 

 

Balance, July 31, 2020

     2,341,765        204,523  
  

 

 

    

 

 

 

 

16


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

13.

LEASES

The Company entered into certain equipment and automobile leases expiring between 2021 and 2023 with interest rates of between 8% and 17% per annum. The Company’s obligations under these finance leases are secured by the lessor’s title to the leased assets. The Company also entered into office leases in January 2018, May 2018, May 2019 and June 2019. With the adoption of IFRS 16, Leases (see Note 3), the Company recognized a lease obligation with regard to the office leases. The terms and the outstanding balances as at July 31, 2020 and April 30, 2020 are as follows:

 

     July 31,
2020
$
     April 30,
2020
$
 

Equipment under lease in monthly instalments of $1,228 with interests of between 13% and 17% per annum. Due dates are between May 2021 and March 2023.

     59,616        71,222  

Equipment under lease in monthly instalments of $22,309 with interest rate of 8% per annum and an end date of May 2023.

     638,227        —    

Automobile under lease in monthly instalments of $1,155 with an interest rate of 8% per annum and an end date of September 2023.

     42,702        43,330  

Right-of-use asset from office lease repayable in monthly instalments of $9,602 and an interest rate of 8% per annum and an end date of May 2021. The obligation includes an early termination fee of $15,981.

     107,598        135,230  

Right-of-use asset from office lease repayable in monthly instalments of $16,445 and an interest rate of 8% per annum and an end date of December 2022.

     458,465        475,727  

Right-of-use asset from office lease repayable in monthly instalments of $23,236 and an interest rate of 8% per annum and an end date of December 2022.

     648,806        673,235  

Right-of-use asset from office lease repayable in monthly instalments of $13,891 to $21,015 and an interest rate of 8% per annum and an end date of April 2023.

     431,258        485,307  

Current portion

     (698,715      (752,306
  

 

 

    

 

 

 

Non-current portion

     1,687,957        1,131,744  
  

 

 

    

 

 

 

As at July 31, 2020, the Company’s lab equipment and automobile include a net carrying amount of $793,557 (April 30, 2020 – $77,285) for the leased equipment and $41,681 (April 30, 2020 – $42,682) for the leased automobile. The net carrying amount of the right-of-use assets from office lease obligation is $1,565,505 (April 30, 2020 – $1,683,285).

 

17


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The following is a schedule of the Company’s future minimum lease payments related to the equipment under finance lease and the office lease obligation:

 

     $  

2021

     835,659  

2022

     982,598  

2023

     780,764  

2024

     16,928  
  

 

 

 

Total minimum lease payments

     2,615,949  

Less: imputed interest

     (229,277
  

 

 

 

Total present value of minimum lease payments

     2,386,672  

Less: Current portion

     (698,715
  

 

 

 

Non-current portion

     1,687,957  
  

 

 

 

 

14.

SHARE CAPITAL

a) Authorized:

Unlimited common shares without par value.

b) Share capital transactions:

2020 Transactions

On March 26, 2020, the Company settled $700,000 of the Debentures plus accrued interest of $46,875 by issuing 1,244,792 common shares (Note 10). The fair value of the 1,244,792 common shares issued was determined to be $858,906. The settlement resulted in a loss of $112,031.

During the year ended April 30, 2020, the Company issued 55,000 common shares pursuant to exercise of stock options for total gross proceeds of $16,500. A value of $12,490 was transferred from contributed surplus to share capital as a result. The weighted average share price at dates the stock options were exercised was $0.69.

During the year ended April 30, 2020, the Company issued 680,971 common shares pursuant to exercise of warrants and finder’s warrants for total gross proceeds of $476,679. A value of $22,942 was transferred from contributed surplus to share capital as a result.

2021 Transactions

On May 1, 2020, the Company issued 664,163 common shares pursuant to the second deferred payment for the acquisition of IPA Europe (Note 6). The common shares were valued at $511,405.

During the three months ended July 31, 2020, the Company issued 180,900 common shares pursuant to exercise of stock options for total gross proceeds of $137,845. A value of $99,199 was transferred from contributed surplus to share capital as a result. The weighted average share price at dates the stock options were exercised was $1.46.

During the three months ended July 31, 2020, the Company issued 3,305,500 common shares pursuant to exercise of warrants and finder’s warrants for total gross proceeds of $3,513,275. A value of $53,199 was transferred from contributed surplus to share capital as a result.

 

18


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

c) Options

The Company has an incentive Stock Option Plan (“the Plan”) under which non-transferable options to purchase common shares of the Company may be granted to directors, officers, employees or service providers of the Company. The terms of the plan provide that the Directors have the right to grant options to acquire common shares of the Company at not less than the closing market price of the shares on the day preceding the grant at terms of up to five years. The maximum number of options outstanding under the Plan shall not result, at any time, in more than 10% of the issued and outstanding common shares.

On October 3 2019, the Company granted 250,000 stock options, exercisable at $0.475 per option, to an officer of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $86,395 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.48, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 1.46%, and an expected life of 5 years.

On October 3, 2019, the Company granted 200,000 stock options, exercisable at $1.00 per option, to a consultant of the Company. The options vested immediately upon grant. The fair value of these options was estimated to be $32,096 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.48, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 1.56%, and an expected life of 2 years.

On October 3, 2019, the Company granted 150,000 stock options, exercisable at $0.50 per option, to a director of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $53,326 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.48, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 1.46%, and an expected life of 5 years.

On October 3, 2019, the Company granted 65,000 stock options, exercisable at $1.01 per option, to employees of the Company. The options vested immediately upon grant. The fair value of these options was estimated to be $14,627 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.48, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 1.54%, and an expected life of 2.96 years.

On April 3, 2020, the Company granted 55,000 stock options, exercisable at $1.01 per option, to employees of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $20,582 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.69, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 0.75%, and an expected life of 3 years.

On April 29, 2020, the Company granted 250,000 stock options, exercisable at $0.76 per option, to an officer of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $129,340 using the Black-Scholes option pricing model and the following assumptions: share price on grant date of $0.76, dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 0.38%, and an expected life of 3.93 years.

Expected volatility was based on the historical volatility of similar companies.

During the three months ended July 31, 2020 the Company has recorded $97,273 (2019 - $285,995) of share-based payments expense.

 

19


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The changes in the stock options for the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     Number of
options
#
     Weighted
average
exercise price
$
     Weighted
average life
remaining
(years)
 

Balance, April 30, 2019 (outstanding)

     5,303,333        0.78        3.87  

Granted

     970,000        0.73        —    

Exercised

     (55,000      0.30        —    

Forfeited

     (903,333      0.73        —    
  

 

 

    

 

 

    

 

 

 

Balance, April 30, 2020 (outstanding)

     5,315,000        0.77        3.03  

Exercised

     (180,900      0.77        —    
  

 

 

    

 

 

    

 

 

 

Balance, July 31, 2020 (outstanding)

     5,134,100        0.77        2.79  

Unvested

     (571,667      0.66        3.81  
  

 

 

    

 

 

    

 

 

 

Exercisable, July 31, 2020

     4,562,433        0.78        2.66  
  

 

 

    

 

 

    

 

 

 

Details of the options outstanding as at July 31, 2020 are as follows:

 

Expiry Date

   Exercise price
$
     Remaining life
(year)
     Options
outstanding
    Unvested      Vested  

October 1, 2021

     1.00        1.17        200,000       —          200,000  

December 20, 2021

     0.30        1.39        510,000 (1)      —          510,000  

September 18, 2022

     1.01        2.13        887,500 (2)      —          887,500  

January 3, 2023

     0.65        2.43        250,000       —          250,000  

February 7, 2023

     0.47        2.52        700,000       —          700,000  

April 3, 2023

     1.01        2.67        55,000 (3)       55,000        —    

September 24, 2023

     0.95        3.15        95,000       —          95,000  

November 7, 2023

     0.80        3.27        121,600 (4)      —          121,600  

November 7, 2023

     0.82        3.27        100,000       —          100,000  

December 31, 2023

     1.00        3.42        1,250,000       —          1,250,000  

January 7, 2024

     0.76        3.44        300,000 (5)      —          300,000  

January 11, 2024

     1.00        3.45        15,000       —          15,000  

April 1, 2024

     0.76        3.67        250,000       250,000        —    

October 1, 2024

     0.475        4.17        250,000       166,667        83,333  

October 3, 2024

     0.50        4.18        150,000       100,000        50,000  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 
     0.77      2.79      5,134,100     571,667      4,562,433  
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

 

(1) 

280,000 of these stock options have been exercised subsequent to July 31, 2020.

(2) 

15,000 of these stock options have been exercised subsequent to July 31, 2020.

(3) 

5,000 of these stock options have been exercised subsequent to July 31, 2020.

(4) 

121,600 of these stock options have been exercised subsequent to July 31, 2020.

(5) 

These options were amended during the year ended April 30, 2020 from an exercise price of $1.00 to $0.76.

 

20


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

d) Warrants

The changes in the warrants for the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     Number of
warrants
#
     Weighted average
exercise price
$
     Weighted average life
remaining (years)
 

Balance, April 30, 2019

     17,732,500        1.04        1.90  

Exercised

     (675,000      0.70        —    
  

 

 

    

 

 

    

 

 

 

Balance, April 30, 2020

     17,057,500        1.05        0.91  

Exercised

     (3,283,500      1.07        —    
  

 

 

    

 

 

    

 

 

 

Balance, July 31, 2020

     13,774,000        1.05        0.70  
  

 

 

    

 

 

    

 

 

 

Details of the warrants outstanding as at July 31, 2020 are as follows:

 

Expiry Date

   Exercise price
$
     Remaining life
(year)
     Warrants
outstanding
 

March 26, 2022

     0.70        1.65        4,998,000 (1) 

September 24, 2020

     1.25        0.15        7,494,000 (2) 

October 25, 2020

     1.25        0.24        1,282,000 (3) 
  

 

 

    

 

 

    

 

 

 
     1.05        0.70        13,774,000  
  

 

 

    

 

 

    

 

 

 

 

(1) 

75,000 of these warrants have been exercised subsequent to July 31, 2020.

(2) 

All of these warrants have been exercised subsequent to July 31, 2020. (3) 244,000 of these warrants have been exercised subsequent to July 31, 2020.

e) Finder’s Warrants

The changes in the finder’s warrants for the three months ended July 31, 2020 and the year ended April 30, 2020 are as follows:

 

     Number of
warrants
#
     Weighted average
exercise price
$
     Weighted average life
remaining (years)
 

Balance, April 30, 2019

     415,942        0.70        2.91  

Exercised

     (5,971      0.70        —    

Balance, April 30, 2020

     409,971        0.70        1.90  

Exercised

     (22,000      0.70        —    
  

 

 

    

 

 

    

 

 

 

Balance, July 31, 2020

     387,971        0.70        1.65  
  

 

 

    

 

 

    

 

 

 

As at July 31, 2020, the Company has 387,971 finder’s warrants outstanding. The warrants have an exercise price of $0.70 per share and expire on March 26, 2022.

 

15.

RELATED PARTY TRANSACTIONS

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management consists of Dr. Jennifer Bath, President and CEO; Lisa Helbling, CFO; Dr. Stefan Lang, Chief Business Officer; Dr. Yasmina Abdiche, Chief Scientific Officer; Charles Wheelock, former Chief Technology Officer; Natasha Tsai, former CFO; Reginald Beniac, former Chief Operating Officer; Oren Beske, former President of ImmunoPrecise Antibodies (USA) Ltd.; Martin Hessing, a former Director of U-Protein; Jos Raats, former President and CEO of IPA Europe; and Directors of the Company. During the three months ended July 31, 2020 and 2019, the compensation for key management is as follows:

 

21


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

     2020
$
     2019
$
 

Management fees

     15,737        45,148  

Salaries and other short-term benefits

     603,895        485,845  

Severance

     62,768        —    

Share-based payments

     90,701        264,882  
  

 

 

    

 

 

 
     773,101        795,875  
  

 

 

    

 

 

 

At July 31, 2020, included in accounts payable and accrued liabilities is $590,197 (April 30, 2020 - $412,188) due to related parties.

During the year ended April 30, 2020, a company controlled by Martin Hessing, a former Director of U-Protein, sold certain equipment to U-Protein for a cash consideration of €25,000.

These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties, unless otherwise noted.

 

16.

SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE

At July 31, 2020 and April 30, 2020, the Company has one reportable segment, being antibody production and related services.

During the three months ended July 31, 2020, the Company had sales to nil (2019 - nil) customer who in aggregate accounted for more than 10% (2019 – 10%) of revenue.

The Company’s revenues are allocated to geographic segments for the three months ended July 31, 2020 and 2019 as follows:

 

     2020
$
     2019
$
 

United States of America

     1,752,079        904,377  

Canada

     291,950        206,823  

Europe

     1,284,203        1,505,926  

Other

     436,745        98,973  
  

 

 

    

 

 

 
     3,764,977        2,716,099  
  

 

 

    

 

 

 

The Company’s revenues are allocated according to revenue types for the three months ended July 31, 2020 and 2019 as follows:

 

     2020
$
     2019
$
 

Project revenue

     3,472,810        2,611,868  

Product sales revenue

     288,232        60,234  

Cryo storage revenue

     3,935        43,997  
  

 

 

    

 

 

 
     3,764,977        2,716,099  
  

 

 

    

 

 

 

 

22


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The Company’s non-current assets are allocated to geographic segments as at July 31, 2020 and April 30, 2020 as follows:

 

     July 31,
2020
$
     April 30,
2020
$
 

North America

     1,981,023        1,429,210  

Netherlands

     18,444,778        18,134,469  
  

 

 

    

 

 

 
     20,425,801        19,563,679  
  

 

 

    

 

 

 

Geographic segmentation of the Company’s net income (loss) for the three months ended July 31, 2020 and 2019 is as follows:

 

     2020
$
     2019
$
 

North America—Corporate

     (680,365      (1,974,763

North America

     (299,074      (112,064

Netherlands

     430,121        74,629  
  

 

 

    

 

 

 
     (549,318      (2,012,198
  

 

 

    

 

 

 

Geographic segmentation of the interest and accretion, and amortization and depreciation for the three months ended July 31, 2020 and 2019 is as follows:

 

Interest and accretion

   2020
$
     2019
$
 

North America—Corporate

     188,474        630,675  

North America

     23,980        23,975  

Netherlands

     58,497        17,203  
  

 

 

    

 

 

 
     270,951        671,853  
  

 

 

    

 

 

 

Amortization and depreciation

   2020
$
     2019
$
 

North America—Corporate

     6,588        20,640  

North America

     180,347        126,771  

Netherlands

     724,988        554,873  
  

 

 

    

 

 

 
     911,923        702,284  
  

 

 

    

 

 

 

 

17.

SUPPLEMENTAL CASH FLOW INFORMATION

 

Non-cash investing and financing transactions:

   July 31,
2020
$
     July 31,
2019
$
 

Acquisition of building and equipment by capital lease

     769,725        1,668,533  

Fair value of shares issued pursuant to deferred acquisition payment to IPA Europe

     511,405        —    

 

23


IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2020 and 2019

(Unaudited – Expressed in Canadian Dollars)

 

 

The following changes in liabilities arose from financing activities:

 

                  Non-cash changes         
     April 30,
2020
$
     Cash Flows
$
    Acquisition
$
     Settlement
/ Disposal
$
    Accretion
$
     Foreign
exchange
movements
and change
in estimates
$
     July 31,
2020
$
 

Deferred acquisition payments

     2,825,440        (518,534     —          (511,405     69,946        110,932        1,976,379  

Debentures

     2,000,000        (2,000,000     —          —         —          —          —    

Convertible debentures

     313,268        1,997,298       —          —         31,199        —          2,341,765  

Loans payable

     312,139        (15,753     —          —         —          —          296,386  

Leases

     1,884,050        (267,103     684,753        —         —          84,972        2,386,672  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

Total

     7,334,897        (804,092     684,753        (511,405     101,145        195,904        7,001,202  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

 

                  Non-cash changes        
     April 30,
2019
$
     Cash Flows
$
    Acquisition
$
     Accretion
$
     Foreign
exchange
movements
and change
in estimates
$
    July 31,
2019
$
 

Deferred acquisition payments

     3,063,981        —         —          457,137        (118,983     3,402,135  

Debentures

     2,708,334        —         —          95,756        —         2,804,090  

Loans payable

     111,670        (20,398     —          —          —         91,272  

Leases

     107,077        (105,075     1,723,277        —          —         1,725,279  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total

     5,991,062        (125,473     1,723,277        552,893        (118,983     8,022,776  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

 

18.

SUBSEQUENT EVENTS

Subsequent to July 31, 2020, the Company granted 250,000 stock options at a price of $1.50 per share for a period of 3 years. The options are subject to following vesting period: 25% at three months after the date of grant and 25% every three months thereafter.

Subsequent to July 31, 2020, the Company granted 1,350,000 stock options at a price of $1.70 per share for a period of 5 years. The options are subject to following vesting period: one-third at six months after the date of grant and one-third every six months thereafter.

 

24